Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

What Was Tested

Researchers studied Liraglutide in this randomized controlled trial publication.

The researchers planned to evaluate the effects of liraglutide on left ventricular function after primary percutaneous coronary intervention for STEMI.

Transthoracic echocardiography was used to assess left ventricular function.

Why It Was Studied

The effects of liraglutide, a glucagon-like peptide-1 analogue, on STEMI patients remain unclear.

Who Took Part

The abstract describes 92 patients taking part.

The age groups tagged for this paper are middle-aged adults, both men and women.

A total of 92 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days.

Eighty-five patients completed the trial.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Liraglutide, giving a reference point.

A time span of 7 days appears in the methods.

What Was Measured

Topics PubMed links to this paper include Echocardiography, Electrocardiography, Hypoglycemic Agents, Liraglutide, Myocardial Infarction, Percutaneous Coronary Intervention and Preoperative Care.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in 92 patients over 7 days.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (American heart journal), a journal based in United States.

More context: the Liraglutide compound page.